v3.25.0.1
Organization and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows as of December 31, 2024 and 2023 (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2024

 

 

2023

 

Cash and cash equivalents

 

$

36,056

 

 

$

41,870

 

Restricted cash

 

 

10,227

 

 

 

15,177

 

Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows

 

$

46,283

 

 

$

57,047

 
Schedule of Basic and Diluted Net Loss per Share Attributable to Stockholders

Basic and diluted net loss per share attributable to stockholders for the years ended December 31, 2024 and 2023 are calculated as follows (in thousands, except share and per share data):

 

 

 

For the Years Ended December 31,

 

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

Net loss

 

$

(186,262

)

 

$

(160,928

)

Denominator:

 

 

 

 

 

 

Shares used to compute net loss per share, basic and diluted

 

 

 

 

 

 

Weighted-average common shares outstanding

 

 

110,596,272

 

 

 

98,153,852

 

Weighted-average pre-funded warrants

 

 

3,088,905

 

 

 

257,310

 

Weighted-average common shares outstanding used to
    compute basic and diluted net loss per share

 

 

113,685,177

 

 

 

98,411,162

 

Net loss per share, basic and diluted

 

 

 

 

 

 

Basic and diluted

 

$

(1.64

)

 

$

(1.64

)
Schedule of Anti-Dilutive Securities not Included in Calculation of Diluted Net Loss Per Common Share

Potentially dilutive securities that are not included in the calculation of diluted net loss per common share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

 

 

 

As of December 31,

 

 

 

2024

 

 

2023

 

Common stock options

 

 

10,722,674

 

 

 

9,850,841

 

Restricted stock units

 

 

6,214,064

 

 

 

3,065,087

 

Series A convertible preferred stock (if converted)

 

 

13,775,430

 

 

 

13,805,540

 

Total

 

 

30,712,168

 

 

 

26,721,468